ConductScience.org, home

Library / Trials

Breath Acetone During Tirzepatide Treatment and Resistance Training in Adults With Obesity

NCT07931235, Not yet recruiting, Technical University of Munich

Trial 9

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

FieldValueSource
TitleBreath Acetone During Tirzepatide Treatment and Resistance Training in Adults With ObesityClinicalTrials.gov
NCT numberNCT07931235ClinicalTrials.gov
StatusNot yet recruitingClinicalTrials.gov
Enrollment150 participants, estimatedClinicalTrials.gov
Lead sponsorTechnical University of MunichClinicalTrials.gov
ConditionsObesity (Disorder)ClinicalTrials.gov
InterventionsStructured resistance training, TirzepatideClinicalTrials.gov
First posted2026-11-12ClinicalTrials.gov
Last updated2026-11-12ClinicalTrials.gov

Registered outcomes 10

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

ListOutcomeTime frameDescriptionSource
PrimaryChange in breath acetone concentration from baseline to end of treatmentBaseline (Week 0) and end of treatment (Week 24)
Breath acetone concentration (ppm) measured under standardized fasting conditions with a handheld point-of-care breath acetone analyzer. Change from baseline to Week 24, compared between the resistance training group and the usual care group, adjusted for baseline.
ClinicalTrials.gov
SecondaryBaseline breath acetone and change in body weightBaseline (Week 0) to Week 24Regression coefficient of the percentage change in body weight (%; calibrated scale) on baseline breath acetone (ppm; handheld breath acetone analyzer)ClinicalTrials.gov
SecondaryBaseline breath acetone and change in fat massBaseline (Week 0) to Week 24Regression coefficient of the change in fat mass (kg; bioelectrical impedance analysis) on baseline breath acetone (ppm; handheld breath acetone analyzer)ClinicalTrials.gov
SecondaryBaseline breath acetone and change in skeletal muscle massBaseline (Week 0) to Week 24Regression coefficient of the change in skeletal muscle mass (kg; bioelectrical impedance analysis) on baseline breath acetone (ppm; handheld breath acetone analyzer)ClinicalTrials.gov
SecondaryBaseline breath acetone and change in thigh muscle volumeBaseline (Week 0) to Week 24Regression coefficient of the change in contractile thigh muscle volume (mL; MRI) on baseline breath acetone (ppm; handheld breath acetone analyzer)ClinicalTrials.gov
SecondaryBaseline breath acetone and change in knee extension strengthBaseline (Week 0) to Week 24Regression coefficient of the change in peak isometric knee extension torque (Nm; isokinetic dynamometer) on baseline breath acetone (ppm; handheld breath acetone analyzer)ClinicalTrials.gov
SecondaryChange in breath acetone concentration from baseline to Week 4Baseline (Week 0) and Week 4Breath acetone concentration (ppm; handheld breath acetone analyzer) under standardized fasting conditions; change from Week 0 to Week 4, compared between groupsClinicalTrials.gov
SecondaryTime course of breath acetone concentration during treatmentWeek 0 to Week 24Breath acetone concentration (ppm; handheld breath acetone analyzer) at Weeks 0, 4, 8, 12, 16, 20 and 24, compared between groupsClinicalTrials.gov
SecondaryPredictive value of early change versus baseline breath acetone for clinical responseBaseline (Week 0) to Week 24
Comparative predictive value of the change in breath acetone concentration from Week 0 to Week 4 versus the baseline (Week 0) breath acetone concentration alone (ppm; handheld breath acetone analyzer) for the percentage change in body weight (%; calibrated scale) from Week 0 to Week 24 (RESIST data).
ClinicalTrials.gov
SecondaryBaseline breath acetone and change in handgrip strengthBaseline (Week 0) to Week 24Regression coefficient of the change in maximum handgrip strength (kg; hand dynamometer) on baseline breath acetone (ppm; handheld breath acetone analyzer)ClinicalTrials.gov

Outcomes 0

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

TypeOutcomeTime framePopulationUnitsMeasured asSource

Results by group 0

Each measurement the trial posted, group by group, in the words and numbers it posted.

OutcomeGroupCategoryValueSpreadUnitsSource

Participant flow 0

How many started, completed or left each group, period by period.

PeriodMilestoneGroupParticipantsUnits countedSource

Adverse events 0

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

TypeEventOrgan systemGroupAffectedAt riskEventsSource

Adverse event totals 0

The totals the trial posted for each group.

TotalGroupAffectedAt riskSource

Papers 0

The papers the trial lists on ClinicalTrials.gov.

PMIDListed asSource

Trial comparisons 0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

ComparisonSource

Tests 0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

TestNamed asSource

Source 4

FieldValueSource
Releasetrials-2026-11-12-0.3.0ClinicalTrials.gov
Release manifest SHA-2564a570df2e7274cee2d4fa2959402fab41880e2cd412e4b590390035fbea69391ClinicalTrials.gov
Registry capture2026-11-12ClinicalTrials.gov
Results copy, AACT2026-03-23ClinicalTrials.gov

The same record as JSON

Release trials-2026-11-12-0.3.0

ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.